Advanced solutions for cancer therapy, including cutting-edge intraperitoneal treatment systems.
Peritoneal cancer remains one of the most challenging frontiers in surgical oncology. Regency brings to India the world’s leading technology platforms for both hyperthermic intraperitoneal chemotherapy (HIPEC) and pressurised intraperitoneal aerosol chemotherapy (PIPAC) — the two most significant advances in locoregional peritoneal cancer treatment.
Our HIPEC systems are deployed in over 200 centres worldwide with more than 20,000 executed treatments. For patients not eligible for CRS-HIPEC, our PIPAC platform offers a minimally invasive, repeatable approach that has demonstrated superiority over systemic IV chemotherapy in randomised data. PIPAC can convert previously inoperable patients to surgical candidates, transforming treatment paradigms in advanced gastric, colorectal, and ovarian cancers.